SCHEMBL3521895

SCHEMBL3521895

Cc1c(OCc2ccccc2)ncn(Cc2ccccc2)c1=O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.60
DAPK1 P53355 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.50
HTT P42858 2/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 1/20 0.46
ADORA2B P29275 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
RECQL P46063 1/20 0.44
MAPK10 P53779 1/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
GRK2 P25098 1/20 0.44
GRK1 Q15835 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520910 0.88 MAPK14 (0.53) MAPK14SMN1; SMN2HPGDMEN1ALDH1A1
SCHEMBL3527246 0.84 MAPK14 (0.59) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3521590 0.83 MAPK14 (0.62) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3522028 0.83 MAPK14 (0.60) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3524527 0.83 MAPK14 (0.60) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3525553 0.82 MAPK14 (0.53) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3521697 0.82 MAPK14 (0.53) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3523796 0.81 MAPK14 (0.55) MAPK14SMN1; SMN2HPGDMEN1ALDH1A1
SCHEMBL3520732 0.81 DAPK1 (0.50) MAPK14DAPK1SMN1; SMN2HTTHPGD
SCHEMBL3520426 0.81 MAPK14 (0.51) MAPK14DAPK1SMN1; SMN2HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885DAPK1 553/4885SMN1; SMN2 912/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 MAPK14 29/4885DAPK1 682/4885SMN1; SMN2 746/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885DAPK1 553/4885SMN1; SMN2 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.